Caris & Co Downgrades Idenix Pharmaceuticals (IDIX) to Above Average
IDIX Hot Sheet
Rating Summary:5 Buy, 5 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 25 | Down: 12 | New: 36
Caris & Co downgrades Idenix Pharmaceuticals (Nasdaq: IDIX) from Buy to Above Average.
To see more analyst ratings on IDIX Click Here.
Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe.
To see more analyst ratings on IDIX Click Here.
Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe.
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- Barclays on U.S. REITs: Best Ideas List: Adding HPP; Removing ARE
- Deutsche Bank Downgrades Nasdaq OMX Group Inc. (NDAQ) to Hold; Upgrading ICE on Lowered Expectations, Higher Volumes
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
